Arrowhead Pharmaceuticals (ARWR) Competitors $18.91 +0.42 (+2.27%) As of 01/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARWR vs. ITCI, ASND, ROIV, RVMD, LEGN, LNTH, ELAN, CYTK, BPMC, and NUVLShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), Lantheus (LNTH), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Blueprint Medicines (BPMC), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Intra-Cellular Therapies Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech Lantheus Elanco Animal Health Cytokinetics Blueprint Medicines Nuvalent Intra-Cellular Therapies (NASDAQ:ITCI) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Which has more risk and volatility, ITCI or ARWR? Intra-Cellular Therapies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Do analysts prefer ITCI or ARWR? Intra-Cellular Therapies currently has a consensus price target of $97.23, indicating a potential downside of 23.55%. Arrowhead Pharmaceuticals has a consensus price target of $43.33, indicating a potential upside of 129.16%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.77Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is ITCI or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Arrowhead Pharmaceuticals N/A -182.69%-64.04% Does the MarketBeat Community prefer ITCI or ARWR? Arrowhead Pharmaceuticals received 23 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. However, 67.75% of users gave Intra-Cellular Therapies an outperform vote while only 65.31% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.75% Underperform Votes24832.25% Arrowhead PharmaceuticalsOutperform Votes54465.31% Underperform Votes28934.69% Which has higher valuation and earnings, ITCI or ARWR? Intra-Cellular Therapies has higher revenue and earnings than Arrowhead Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$612.78M22.00-$139.67M-$0.87-146.20Arrowhead Pharmaceuticals$3.55M662.64-$599.49M-$5.02-3.77 Do insiders and institutionals have more ownership in ITCI or ARWR? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer ITCI or ARWR? In the previous week, Intra-Cellular Therapies had 19 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 35 mentions for Intra-Cellular Therapies and 16 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.82 beat Intra-Cellular Therapies' score of 0.41 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 6 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIntra-Cellular Therapies beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.35B$6.66B$5.31B$8.81BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-3.7710.3186.4016.81Price / Sales662.64189.061,120.86115.13Price / CashN/A57.6843.2437.79Price / Book12.284.975.104.88Net Income-$599.49M$153.46M$122.01M$228.12M7 Day Performance-3.86%-6.40%-3.86%-3.81%1 Month Performance-13.46%-1.38%0.08%0.01%1 Year Performance-48.09%-3.38%25.24%13.15% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.2215 of 5 stars$18.91+2.3%$43.33+129.2%-48.1%$2.35B$3.55M-3.77400Positive NewsITCIIntra-Cellular Therapies3.0943 of 5 stars$82.52-1.4%$97.23+17.8%+91.7%$8.75B$612.78M-94.85560Analyst ForecastNews CoverageGap UpASNDAscendis Pharma A/S3.5163 of 5 stars$140.90+0.4%$191.77+36.1%+2.1%$8.55B$327.43M-17.44640Short Interest ↓News CoveragePositive NewsROIVRoivant Sciences3.1433 of 5 stars$11.70+0.1%$17.93+53.2%-2.9%$8.52B$129.13M2.07860Positive NewsRVMDRevolution Medicines4.5937 of 5 stars$44.40+0.6%$65.82+48.2%+49.4%$7.47B$742,000.00-12.37443Positive NewsLEGNLegend Biotech2.3999 of 5 stars$35.43-1.0%$80.62+127.5%-46.5%$6.47B$520.18M-37.291,800Short Interest ↓LNTHLantheus4.2821 of 5 stars$92.64+1.6%$131.86+42.3%+68.3%$6.44B$1.50B15.41834Short Interest ↑News CoveragePositive NewsELANElanco Animal Health4.4182 of 5 stars$12.15+1.4%$16.71+37.6%-24.6%$6.01B$4.45B30.389,300CYTKCytokinetics4.0808 of 5 stars$49.22-0.3%$83.64+69.9%-45.4%$5.81B$3.22M-9.15250Analyst ForecastNews CoverageBPMCBlueprint Medicines1.5574 of 5 stars$90.69+2.6%$123.33+36.0%+24.6%$5.76B$434.42M-42.98640Analyst ForecastShort Interest ↑News CoverageGap UpNUVLNuvalent1.7131 of 5 stars$81.00+0.3%$112.36+38.7%-3.5%$5.76BN/A-23.3440Analyst Forecast Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Lantheus Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARWR) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersGreatest crypto bull market in history?A crypto storm is coming Right now, conditions are in place for a historic move we expect will be the great...Stansberry Research | Sponsored$24 trillion tech spotted at Mar-a-Lago?President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…Centurion Publishing | SponsoredTrump’s 2nd Term Shocker: New AI ComingForget Nvidia. Legendary investor Louis Navellier is recommending this little-known company because it's he...10 Minute Trades | Sponsored Check Out these Stocks Before Trump’s InaugurationAs soon as Trump takes power this coming January 20… He could send these “Trump stocks” higher than anyone ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
